Product Description
Mechanisms of Action: STAT3 Inhibitor, IL1A Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: China | Egypt | India | Indonesia | Japan | Korea | Malaysia | Pakistan | Peru | Philippines | Russia | Thailand | Ukraine | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Otsuka
Company Location: NEW YORK NY 10271
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Dyspepsia|Stomach Ulcer|Gastritis|Helicobacter Infections|Esophagitis, Peptic|Gastroesophageal Reflux|Dry Eye Syndromes|Sjogren's Syndrome|Stomach Diseases|Keratoconjunctivitis Sicca
Phase 3: Keratoconjunctivitis Sicca|Stomach Ulcer|Dry Eye Syndromes|Osteoarthritis|Arthritis, Rheumatoid|Spondylitis, Ankylosing|Gastritis|Gastritis, Atrophic|Dyspepsia|Signs and Symptoms, Digestive
Phase 2: Head and Neck Cancer|Colitis, Ulcerative|Sjogren's Syndrome|Mucositis|Xerostomia|Dry Eye Syndromes|Keratoconjunctivitis Sicca|Arthritis, Rheumatoid|Stomatitis|Oral Ulcer|Behcet Syndrome|Other
Phase 1: Healthy Volunteers|Other|Dry Eye Syndromes|Keratoconjunctivitis Sicca|Gastritis|Edema
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05166304 |
MUFMIRB App N. 1007/12/2023 | P2 |
Completed |
Arthritis, Rheumatoid |
2025-08-01 |
2025-11-21 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT06084624 |
NCT06084624 | P2 |
Unknown status |
Oral Ulcer|Behcet Syndrome |
2025-01-01 |
2025-11-01 |
Primary Endpoints|Treatments|Trial Status |
|
ChiCTR2300078984 |
ChiCTR2300078984 | N/A |
Recruiting |
Gout |
2024-12-31 |
2023-12-22 |
Treatments |
|
CTR20243901 |
CTR20243901 | N/A |
Completed |
Gastritis|Edema |
2024-12-24 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT05048069 |
MCTSRPMS | N/A |
Unknown status |
Gastritis |
2024-12-15 |
2025-10-01 |
Primary Endpoints|Treatments|Trial Status |
|
CTR20242604 |
CTR20242604 | N/A |
Completed |
Edema|Gastritis |
2024-09-09 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
ChiCTR2200063492 |
ChiCTR2200063492 | N/A |
Not yet recruiting |
Gastritis, Atrophic |
2024-08-29 |
|||
CTR20240809 |
CTR20240809 | N/A |
Completed |
Edema|Gastritis |
2024-06-07 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20240111 |
CTR20240111 | N/A |
Completed |
Edema|Gastritis |
2024-02-04 |
2025-04-29 |
||
CTR20232354 |
CTR20232354 | N/A |
Completed |
Edema|Gastritis |
2024-01-29 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT04649697 |
CEBC-CU-2020-9 | P3 |
Unknown status |
Arthritis, Rheumatoid |
2023-12-30 |
2025-10-01 |
Primary Endpoints|Treatments|Trial Status |
|
CTR20232607 |
CTR20232607 | N/A |
Completed |
Edema|Gastritis |
2023-12-19 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20230932 |
CTR20230932 | N/A |
Completed |
Gastritis|Edema |
2023-06-24 |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20230774 |
CTR20230774 | N/A |
Completed |
Gastritis|Edema |
2023-05-31 |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20230569 |
CTR20230569 | N/A |
Completed |
Edema|Gastritis |
2023-05-13 |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20230218 |
CTR20230218 | N/A |
Completed |
Edema|Gastritis |
2023-04-05 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20223288 |
CTR20223288 | N/A |
Completed |
Edema|Gastritis |
2023-03-24 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20223436 |
CTR20223436 | N/A |
Completed |
Gastritis|Edema |
2023-01-16 |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20222377 |
CTR20222377 | N/A |
Completed |
Edema|Gastritis |
2023-01-06 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20222585 |
CTR20222585 | N/A |
Completed |
Gastritis|Edema |
2022-12-07 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20222044 |
CTR20222044 | N/A |
Completed |
Edema|Gastritis |
2022-10-18 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20221629 |
CTR20221629 | N/A |
Completed |
Gastritis|Edema |
2022-09-28 |
2025-04-29 |
Primary Completion Date |
|
CTR20221777 |
CTR20221777 | N/A |
Completed |
Gastritis|Edema |
2022-09-21 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20213424 |
CTR20213424 | P1 |
Completed |
Edema|Gastritis |
2022-08-09 |
2025-04-29 |
||
CTR20220981 |
CTR20220981 | N/A |
Completed |
Gastritis|Edema |
2022-08-01 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |